Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RIGL

Rigel Pharmaceuticals

Sep 12 • 04:00PM ET

37.96

+0.14 0.37 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY NVAX VKTX ARWR ACAD ENTA KURA AMRN ANAB

| Held by: IWM VTI XBI JSMD IWO VXF IBB FFTY FDM JSML

Scroll to Statements

Index	RUT	P/E	7.01	EPS (ttm)	5.41	Insider Own	2.70%	Shs Outstand	17.94M	Perf Week	-8.18%
Market Cap	680.90M	Forward P/E	10.48	EPS next Y	3.62	Insider Trans	0.00%	Shs Float	17.45M	Perf Month	3.77%
Enterprise Value	633.56M	PEG	0.12	EPS next Q	0.90	Inst Own	77.71%	Short Float	11.49%	Perf Quarter	78.22%
Income	97.82M	P/S	2.54	EPS this Y	462.47%	Inst Trans	-0.93%	Short Ratio	3.93	Perf Half Y	90.66%
Sales	267.92M	P/B	8.31	EPS next Y	-34.97%	ROA	58.38%	Short Interest	2.01M	Perf YTD	125.68%
Book/sh	4.57	P/C	6.28	EPS next 5Y	56.66%	ROE	376.09%	52W High	43.72 -13.17%	Perf Year	195.41%
Cash/sh	6.04	P/FCF	10.35	EPS past 3/5Y	- -	ROIC	81.45%	52W Low	12.76 197.49%	Perf 3Y	163.61%
Dividend Est.	-	EV/EBITDA	5.92	Sales past 3/5Y	6.30% 24.77%	Gross Margin	91.52%	Volatility	6.75% 6.00%	Perf 5Y	64.33%
Dividend TTM	-	EV/Sales	2.36	EPS Y/Y TTM	775.39%	Oper. Margin	39.04%	ATR (14)	2.13	Perf 10Y	30.90%
Dividend Ex-Date	-	Quick Ratio	1.90	Sales Y/Y TTM	105.62%	Profit Margin	36.51%	RSI (14)	56.17	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	5691.65%	SMA20	-4.17%	Beta	1.26	Target Price	41.20
Payout	0.00%	Debt/Eq	0.75	Sales Q/Q	176.01%	SMA50	27.58%	Rel Volume	0.74	Prev Close	37.82
Employees	164	LT Debt/Eq	0.47	Earnings	Aug 05 AMC	SMA200	69.65%	Avg Volume	509.99K	Price	37.96
IPO	Nov 29, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	27.13% 14.32%	Trades		Volume	379,170	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-23	Resumed	Piper Sandler	Neutral	$2
Jun-09-22	Downgrade	Citigroup	Buy → Neutral
Jun-08-22	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $1
Jun-08-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$6 → $1
Mar-23-22	Initiated	B. Riley Securities	Neutral	$4
Nov-09-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-15-19	Resumed	Cantor Fitzgerald	Overweight	$7 → $5
Sep-26-19	Resumed	JP Morgan	Overweight	$7
Mar-01-19	Reiterated	Cantor Fitzgerald	Overweight	$9 → $7
Aug-27-18	Initiated	Citigroup	Buy	$8.50
May-02-18	Reiterated	Cantor Fitzgerald	Overweight	$6 → $9
Dec-21-17	Resumed	Piper Jaffray	Overweight	$6
Dec-15-17	Initiated	Cantor Fitzgerald	Overweight	$6
Nov-06-17	Resumed	H.C. Wainwright	Buy	$7
Mar-09-17	Reiterated	H.C. Wainwright	Buy	$6 → $5
Aug-31-16	Reiterated	H.C. Wainwright	Buy	$6 → $7
Aug-30-16	Reiterated	Piper Jaffray	Overweight	$10 → $11
Jul-13-16	Initiated	H.C. Wainwright	Buy	$6
Jun-13-16	Initiated	Piper Jaffray	Overweight
Apr-22-16	Upgrade	JP Morgan	Neutral → Overweight

Show Previous Ratings

Sep-11-25 09:48AM	Can Tavalisse Drive Rigel's Growth Through the Rest of 2025? (Zacks)
Sep-09-25 12:00PM	What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now? (Zacks) -12.09%
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-05-25 09:09AM	Do Options Traders Know Something About RIGL Stock We Don't? (Zacks)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
01:57PM	Loading…
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Aug-26-25 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-25-25 02:03PM	Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock? (Zacks)
10:15AM	This Darling Pharma Stock Is Hitting New Highs, But the Momentum Could Run Out Soon (Barchart)
09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out? (Zacks)
Aug-22-25 09:04AM	Target Stock Market Leaders Rising In Heavy Volume With This Powerful Screen (Investor's Business Daily)
Aug-20-25 12:45PM	Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU (Zacks) +6.21%
Aug-15-25 09:50AM	SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease (Zacks)
Aug-12-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
09:11AM	H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT (Insider Monkey)
12:20PM	Loading…
Aug-08-25 12:20PM	Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy? (Zacks)
10:00AM	Best Momentum Stock to Buy for August 8th (Zacks)
09:15AM	5 Best Stocks With Relative Price Strength to Buy Right Now (Zacks)
06:09AM	New Strong Buy Stocks for August 8th (Zacks)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
09:55AM	Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-06-25 03:29AM	Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com) +22.98%
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks) +6.93%
05:04PM	Rigel: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-04-25 10:00AM	Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-30-25 12:10PM	Why Rigel (RIGL) Could Beat Earnings Estimates Again (Zacks) +5.58%
09:55AM	Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect? (Zacks)
09:40AM	Loading…
09:40AM	Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now? (Zacks)
Jul-29-25 08:05AM	Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update (PR Newswire)
Jul-10-25 11:14AM	H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL) (Insider Monkey)
Jul-07-25 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-29-25 09:40AM	Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? (Zacks)
May-28-25 09:55AM	Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High? (Zacks)
08:05AM	Rigel to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-22-25 05:20PM	Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress (PR Newswire) -5.78%
May-14-25 09:55AM	Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-13-25 09:40AM	Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now? (Zacks)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-09-25 12:20PM	Earnings Estimates Rising for Rigel (RIGL): Will It Gain? (Zacks)
May-08-25 09:55AM	Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet (Zacks)
May-07-25 06:16PM	Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum (Seeking Alpha)
03:18AM	Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 11:13PM	Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	Rigel Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
May-05-25 10:14AM	Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-01-25 05:35PM	Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-29-25 08:05AM	Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update (PR Newswire)
Apr-24-25 07:05AM	Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-17-25 12:00PM	Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:21AM	4 Healthcare Stocks to Buy as the Sector Faces Government Heat (Zacks)
Apr-04-25 03:31PM	Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability (Seeking Alpha)
08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Mar-27-25 08:05AM	Rigel Announces Settlement Agreement Resolving TAVALISSE (fostamatinib disodium hexahydrate) Patent Litigation (PR Newswire)
Mar-10-25 08:05AM	Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors (PR Newswire)
Mar-05-25 10:25AM	Q4 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.11%
09:55AM	Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade (Zacks)
02:08AM	Rigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Mar-04-25 05:15PM	Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:23PM	Rigel: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Mar-03-25 07:14AM	Rigel Pharmaceuticals Inc (RIGL) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-25-25 08:05AM	Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update (PR Newswire)
Feb-03-25 09:55AM	Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect? (Zacks)
Jan-23-25 07:27AM	Rigel enrols first subject in Phase I sickle cell disease therapy trial (Clinical Trials Arena)
Jan-22-25 08:05AM	Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease (PR Newswire)
Jan-17-25 09:55AM	Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know (Zacks) +16.02%
Jan-15-25 12:00PM	Rigel (RIGL) Upgraded to Buy: Here's Why (Zacks) +7.91%
Jan-13-25 08:05AM	Rigel Provides Business Update and 2025 Outlook (PR Newswire) +5.29%
Jan-09-25 08:05AM	Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS (PR Newswire)
Jan-08-25 08:05AM	Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-03-25 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-09-24 12:02PM	Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition (PR Newswire) -9.00%
Dec-02-24 08:05AM	Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS (PR Newswire)
Nov-19-24 09:55AM	How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% (Zacks) +5.15%
Nov-12-24 08:05AM	Rigel to Present at the Jefferies London Healthcare Conference (PR Newswire) +9.10%
Nov-08-24 09:48AM	Q3 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +42.94%
02:27AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 05:15PM	Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates (Zacks)
04:09PM	Rigel: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-06-24 07:42AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-05-24 09:05AM	Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Oct-31-24 08:05AM	Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update (PR Newswire)
Oct-24-24 04:35PM	Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO (pralsetinib) (PR Newswire)
Oct-16-24 10:00AM	Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE (GlobeNewswire)
Oct-04-24 08:05AM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-25-24 04:34AM	Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? (Zacks)
Sep-12-24 08:05AM	Rigel to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire)
Sep-06-24 06:32AM	Rigel enrols first participant in Phase Ib/II AML treatment regimen trial (Clinical Trials Arena)
Sep-05-24 07:30AM	Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (olutasidenib) in mIDH1 AML (PR Newswire)
Sep-03-24 08:00AM	Rigel Expands Relationship with Kissei to include REZLIDHIA (olutasidenib) in Japan, the Republic of Korea and Taiwan (PR Newswire)
Aug-29-24 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire) +5.04%
Aug-07-24 11:12AM	Q2 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.79%
Aug-06-24 05:30PM	Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.02%
04:25PM	Rigel: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schorno Dean L	EVP & Chief Financial Officer	Feb 04 '25	Sale	20.92	2,036	42,595	58,969	Feb 06 08:27 PM
Schorno Dean L	EVP & Chief Financial Officer	Feb 05 '25	Sale	21.93	1,734	38,020	57,235	Feb 06 08:27 PM
Santos David A	EVP, Chief Commercial Officer	Feb 04 '25	Sale	20.92	2,125	44,457	53,500	Feb 06 08:27 PM
Santos David A	EVP, Chief Commercial Officer	Feb 05 '25	Sale	21.93	1,796	39,379	51,704	Feb 06 08:27 PM
RODRIGUEZ RAUL R	CEO, President	Feb 04 '25	Sale	20.92	4,952	103,601	243,854	Feb 06 08:27 PM
RODRIGUEZ RAUL R	CEO, President	Feb 05 '25	Sale	21.93	4,400	96,474	239,454	Feb 06 08:27 PM
Furey Raymond J.	EVP, GC, CCO & Corp Sec	Feb 04 '25	Sale	20.92	1,448	30,294	40,169	Feb 06 08:26 PM
Furey Raymond J.	EVP, GC, CCO & Corp Sec	Feb 05 '25	Sale	21.93	1,339	29,359	38,830	Feb 06 08:26 PM
Santos David A	Officer	Feb 05 '25	Proposed Sale	21.93	1,796	39,379		Feb 05 03:58 PM
Schorno Dean L	Officer	Feb 05 '25	Proposed Sale	21.93	1,734	38,020		Feb 05 03:43 PM
Furey Raymond J.	Officer	Feb 05 '25	Proposed Sale	21.93	1,339	29,359		Feb 05 03:41 PM
RODRIGUEZ RAUL R	Officer	Feb 05 '25	Proposed Sale	21.93	4,400	96,474		Feb 05 03:40 PM
Schorno Dean L	Officer	Feb 04 '25	Proposed Sale	20.92	2,036	42,596		Feb 04 04:39 PM
RODRIGUEZ RAUL R	Officer	Feb 04 '25	Proposed Sale	20.92	4,952	103,602		Feb 04 04:30 PM
Furey Raymond J.	Officer	Feb 04 '25	Proposed Sale	20.92	1,448	30,294		Feb 04 04:21 PM
Santos David A	Officer	Feb 04 '25	Proposed Sale	20.92	2,125	44,458		Feb 04 04:20 PM
RODRIGUEZ RAUL R	CEO, President	Jan 24 '25	Option Exercise	21.40	90,000	1,926,000	250,584	Jan 28 08:49 PM
Masuda Esteban	Officer	Jan 24 '25	Proposed Sale	22.14	4,999	110,678		Jan 24 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RIGL

Rigel Pharmaceuticals

Upgrade your FINVIZ experience